February 21, 2025

FDA Approves First Cerebrotendinous Xanthomatosis Treatment

The FDA has approved Ctexli (chenodiol) as the first treatment for cerebrotendinous xanthomatosis, a rare lipid storage disorder.

Conexiant

February 21, 2025

FDA Ends Semaglutide Shortage, Updates Policy

FDA declares resolution of nationwide semaglutide injection shortage and outlines 60 to 90 day transition periods for compounding facilities while other GLP-1 medications remain in limited supply.

Conexiant

February 14, 2025

First Rapid-Acting Insulin Biosimilar Gets FDA Approval

FDA approves Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog for glycemic control in adult and pediatric diabetes patients, expanding treatment accessibility.

Conexiant

February 12, 2025

Phase III Trial Targets Venous Leg Ulcers

With no new FDA-approved drugs for chronic wound debridement since 1965, MediWound's phase 3 trial tests EscharEx for venous leg ulcers in 216 patients.

Reuters

February 06, 2025

FDA: Diabetes Device Alerts May Fail

FDA warns of safety risks associated with smartphone-connected diabetes devices, citing missed alerts leading to severe complications including death.

Conexiant

February 03, 2025

FDA Monthly Round-Up: Key January Updates

January's FDA approvals include therapeutic advancements across neurology, oncology, pain management, and more.

Conexiant

January 28, 2025

FDA Approves New Indication for Semaglutide in Type 2 Diabetes With CKD

This marks the third FDA–approved indication for semaglutide.

Conexiant

January 27, 2025

Enobosarm Combo Cuts Muscle Loss: Study

Investigational drug in combination with weight-loss treatment preserves lean muscle mass in older patients with obesity, showing promising potential for reducing adiposity and achieving greater weight reduction.

Reuters

January 27, 2025

Long-Term Effects of COVID-19 Reinfections

“Each subsequent infection could potentially increase the burden on the immune system, leaving individuals vulnerable to the cumulative effects of the virus."

Conexiant